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Background: Long-term aspirin prevents vascular events but is only
modestly effective. Rivaroxaban alone or in combination with aspirin
might be more effective than aspirin alone for vascular prevention in
patients with stable coronary artery disease (CAD) or peripheral artery
disease (PAD). Rivaroxaban as well as aspirin increase upper gastro-
intestinal (GI) bleeding and this might be prevented by proton pump
inhibitor therapy.
Methods: Cardiovascular Outcomes for People Using Anticoagulation
Strategies (COMPASS) is a double-blind superiority trial comparing
rivaroxaban 2.5 mg twice daily combined with aspirin 100 mg once
daily or rivaroxaban 5 mg twice daily vs aspirin 100 mg once daily for
prevention of myocardial infarction, stroke, or cardiovascular death in
patients with stable CAD or PAD. Patients not taking a proton pump
inhibitor were also randomized, using a partial factorial design, to
pantoprazole 40 mg once daily or placebo. The trial was designed to
have at least 90% power to detect a 20% reduction in each of the
rivaroxaban treatment arms compared with aspirin and to detect a
50% reduction in upper GI complications with pantoprazole compared
with placebo.RESUME
Contexte : Un traitement à long terme par l’acide acetylsalicylique
previent les accidents vasculaires, mais son efficacite reste modeste.
Le rivaroxaban seul ou en association avec l’acide acetylsalicylique
serait plus efficace que l’acide acetylsalicylique seul pour prevenir les
accidents vasculaires chez les patients atteints de coronaropathie ou
d’arteriopathie peripherique stables. Le rivaroxaban et l’acide
acetylsalicylique augmentent tous deux les saignements gastro-
intestinaux, et cet effet indesirable pourrait être contre à l’aide d’un
inhibiteur de la pompe à protons.
Methodes : L’essai COMPASS (Cardiovascular Outcomes for People
Using Anticoagulation Strategies) est un essai de superiorite à double
insu comparant ou le rivaroxaban à raison de 5 mg, 2 fois par jour vs
l’acide acetylsalicylique à raison de 100 mg, 1 fois par jour dans la
prevention de l’infarctus du myocarde, de l’accident vasculaire cerebral
ou du decès d’origine cardiovasculaire chez des patients atteints de
coronaropathie ou d’arteriopathie peripherique stables. Les patients
qui ne prenaient pas un inhibiteur de la pompe à protons ont aussi ete
repartis au hasard selon un plan factoriel partiel, pour recevoir le
pantoprazole à raison de 40 mg, une fois par jour, ou un placebo.Cardiovascular (CV) disease is responsible for approximately treatment reduces the risk of gastrointestinal (GI) bleeding in
10one-third of deaths in persons aged 35 years or older. An
estimated 17.3 million people worldwide died of CV disease
in 2012 and this number is projected to increase to 23.6
million per year by 2030.1 Coronary artery disease (CAD) and
peripheral arterial disease (PAD) are strong predictors of risk
for future CV events.1,2
Aspirin, statins, angiotensin modulators, and b-blockers
are effective and widely used for CV prevention in patients
with CAD, and the first 3 classes of drugs are effective also in
patients with PAD. However, despite use of these therapies, as
many as 5% of patients experience recurrent vascular events
each year.3 A more effective antithrombotic therapy than
aspirin could have a major effect in further reducing the risk of
nonfatal and fatal CV events in this population.
Rivaroxaban is a selective direct coagulation factor Xa in-
hibitor that has been shown in large randomized controlled
trials to be effective for the prevention and treatment of
venous thromboembolism and for prevention of stroke or
systemic embolism in patients with atrial fibrillation.4-7 In
patients with a recent acute coronary syndrome, rivaroxaban
given at a dose of 2.5 mg or 5 mg twice daily reduced the risk
of nonfatal and fatal CV events.8 This vascular protective dose
of rivaroxaban could be a promising option for reducing the
risk of recurrent events in patients with stable CAD or PAD.
Bleeding is the most common complication of antith-
rombotic therapy and predicts subsequent CV events.9
Although the mechanisms linking bleeding with an
increased risk of CV events after bleeding remain poorly un-
derstood, prevention of bleeding can be expected to avoid
related morbidity and mortality. Proton pump inhibitorpatients treated with dual antiplatelet therapy, but has not
been tested in patients treated with anticoagulant therapy.
Evidence for efficacy of antithrombotic therapy for CV
prevention in CAD and PAD
Aspirin reduces the risk of myocardial infarction (MI),
stroke, or CV death by one-fifth in patients with CAD, ce-
rebrovascular disease, or PAD.11 Aspirin is also effective for
prevention of graft failure after coronary artery bypass graft
(CABG) surgery,11 but despite its use as many as 40% of
patients have at least 1 obstructed graft within 1 year.12 Graft
failure is an independent predictor of MI and death.
Various antiplatelet regimens as well as warfarin have been
tested as alternatives to aspirin alone for long-term secondary
CV prevention. Compared with aspirin, clopidogrel produced
a modest reduction in MI, stroke, or CV death.13 The com-
bination of aspirin and clopidogrel did not reduce major
adverse CV events compared with aspirin alone,14 but a
benefit was evident in the subgroup of patients with a history
of symptomatic disease.15 Long-term treatment with the
combination of aspirin and dipyridamole or aspirin and tica-
grelor compared with aspirin alone, or the combination of
vorapaxar with standard antiplatelet therapy also yielded
benefits but none of these approaches reduced mortality.16-18
The combination of aspirin and warfarin compared with
aspirin alone reduced the risk of recurrent MI in patients with
a recent acute coronary syndrome but increased bleeding and
did not reduce mortality.19-21 Warfarin has many drug and
food interactions and its use is further complicated by the
Results: Between February 2013 and May 2016, we recruited 27,395
participants from 602 centres in 33 countries; 17,598 participants
were included in the pantoprazole vs placebo comparison. At baseline,
the mean age was 68.2 years, 22.0% were female, 90.6% had CAD,
and 27.3% had PAD.
Conclusions: COMPASS will provide information on the efficacy and
safety of rivaroxaban, alone or in combination with aspirin, in the long-
term management of patients with stable CAD or PAD, and on the
efficacy and safety of pantoprazole in preventing upper GI complica-
tions in patients receiving antithrombotic therapy.
L’essai a ete conçu de manière à avoir une puissance d’au moins 90 %
pour deceler une reduction de 20 % dans chacun des groupes recevant
le rivaroxaban comparativement à l’acide acetylsalicylique, et une
reduction de 50 % des complications des voies digestives hautes dans
le groupe recevant le pantoprazole comparativement au placebo.
Resultats : De fevrier 2013 à mai 2016, nous avons recrute 27 395
participants de 602 centres dans 33 pays; 17 598 participants ont ete
inclus dans la comparaison entre le pantoprazole et le placebo. Au
depart, l’âge moyen etait de 68,2 ans, 22,0 % des patients etaient des
femmes, 90,6 % etaient atteints de coronaropathie et 27,3 %
d’arteriopathie peripherique.
Conclusions : L’etude COMPASS fournira des renseignements sur
l’efficacite et l’innocuite du rivaroxaban, seul ou en association à
l’acide acetylsalicylique, dans le traitement à long terme de patients
atteints de coronaropathie ou d’arteriopathie peripherique stables, et
sur l’efficacite et l’innocuite du pantoprazole dans la prevention des
complications des voies digestives hautes chez des patients recevant
un traitement antithrombotique.
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COMPASS Trial Designneed for routine coagulation monitoring. In patients with
PAD, the combination of aspirin and warfarin did not reduce
ischemic events and markedly increased bleeding, although a
benefit was suggested in an exploratory post hoc analysis that
excluded patients with bleeding.22 The evidence of efficacy of
warfarin after acute coronary syndrome and the suggestion of
a benefit in PAD among participants who did not experience
bleeding support the rationale for testing a safer and more
convenient anticoagulant as an alternative to or in addition to
aspirin for secondary prevention of CV events.
Rivaroxaban was tested as add-on therapy to standard of
care in patients with a recent acute coronary syndrome in the
Anti-Xa Therapy to Lower Cardiovascular Events in Addition
to Standard Therapy in Subjects with Acute Coronary
Syndrome - Thrombolysis InMyocardial Infarction-51 (ATLAS
TIMI-51) trial. At doses of 2.5 mg or 5 mg twice daily, rivar-
oxaban compared with placebo reduced the risk of MI, stroke, or
CV death by 16% (hazard ratio [HR], 0.84; 95% confidence
interval [CI], 0.74-0.96; P ¼ 0.008) and stent thrombosis by
31% (HR, 0.69; 95% CI, 0.51-0.93; P ¼ 0.02). The 2.5 mg
twice daily dose also reduced total mortality (HR, 0.68; 95%CI,
0.53-0.87; P ¼ 0.002).8 Most participants (n ¼ 14,473) also
received the combination of aspirin and clopidogrel, and this
might explain the increase inmajor and intracranial bleedingwith
both doses of rivaroxaban, and especially with the 5-mg twice
daily dose. On a background of aspirin alone (n ¼ 1053),
rivaroxaban compared with placebo produced consistent benefits
and appeared to be associated with no excess of major bleeding.
Prevention of upper GI events
Upper GI tract bleeding is the most common complication
in patients receiving antithrombotic therapy.23-25 Proton
pump inhibitors are effective for the prevention of upper GI
bleeding in patients treated with dual antiplatelet therapy10
but have not been tested in a randomized trial for preven-
tion of GI tract complications in patients treated with anti-
coagulants. Observational study results have meanwhile fueled
concerns that long-term proton pump inhibitor therapy might
be associated with an increased risk of serious adverse out-
comes, including pneumonia, enteric infection, osteoporosis,chronic kidney disease, and cognitive decline.26-28 These as-
sociations might relate to residual confounding and it is
important that benefits and potential long-term safety con-
cerns be evaluated in a randomized trial.
Cardiovascular Outcomes for People Using
Anticoagulation Strategies (COMPASS) Trial
Specific objectives
Primary objectives for rivaroxaban randomization. The
primary objectives for rivaroxaban randomization are to: (1)
determine whether rivaroxaban 2.5 mg twice daily with
aspirin 100 mg once daily compared with aspirin 100 mg
once daily reduces the risk of the composite outcome of MI,
stroke, or CV death in participants with stable CAD or PAD;
and (2) determine whether rivaroxaban 5 mg twice daily
compared with aspirin 100 mg once daily reduces the risk of
the composite outcome of MI, stroke, or CV death in par-
ticipants with stable CAD or PAD.
Secondary objectives for rivaroxaban randomization. The
secondary objectives for rivaroxaban randomization are to: (1)
determine whether rivaroxaban 2.5 mg twice daily with
aspirin 100 mg once daily, or rivaroxaban 5 mg twice daily
compared with aspirin 100 mg once daily reduces the risk of
the composite of major thrombotic events (coronary heart
disease death, MI, ischemic stroke, or acute limb ischemia;
and CV death, MI, ischemic stroke, acute limb ischemia) in
participants with stable CAD or PAD; and (2) determine
whether rivaroxaban 2.5 mg twice daily with aspirin 100 mg
once daily, or rivaroxaban 5 mg twice daily compared with
aspirin 100 mg once daily reduces the risk of all-cause mor-
tality in participants with stable CAD or PAD.
Main objective for pantoprazole randomization. The
main objective for pantoprazole randomization was to deter-
mine whether pantoprazole 40 mg once daily compared with
placebo reduces the risk of upper GI bleeding, ulceration,
obstruction, or perforation in participants with stable CAD or
PAD receiving antithrombotic therapy.
Table 1. COMPASS trial eligibility
Coronary artery disease, defined as:
 Myocardial infarction within the past 20 years, or
 Multivessel coronary disease* with symptoms or with history
of stable or unstable angina, or
 Multivessel percutaneous coronary intervention, or
 Multivessel CABG surgery
Peripheral arterial disease, defined as:
 Previous aortofemoral bypass surgery, limb bypass surgery,
or percutaneous transluminal angioplasty revascularization
of the iliac, or infrainguinal arteries, or
 Previous limb or foot amputation for arterial vascular disease, or
 History of intermittent claudication and 1 or more of the following:
(1) an ankle/arm blood pressure ratio < 0.90, or
(2) significant peripheral artery stenosis ( 50%)
documented using angiography, or duplex ultrasound, or
(3) Previous carotid revascularization or asymptomatic
carotid artery stenosis  50% as diagnosed using
duplex ultrasound or angiography
CABG, coronary artery bypass graft; COMPASS, Cardiovascular Out-
comes for People Using Anticoagulation Strategies.
* Refers to stenosis of  50% in 2 or more coronary arteries, confirmed
using invasive coronary angiography, or noninvasive imaging or stress studies
(eg, exercise or pharmacologic) suggestive of significant ischemia in  2
coronary territories; or in 1 coronary territory if at least 1 other territory has
been revascularized.
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COMPASS is a phase III, event-driven, blinded, ran-
domized controlled trial with a 3  2 partial factorial design
that is sponsored by Bayer AG. The steering committee,
comprised of Population Health Research Institute (PHRI)
investigators, the National Leaders, and sponsor representa-
tives, was responsible for development of the protocol and is
responsible for the conduct and oversight of the study. The
protocol was approved by institutional review boards and
health authorities in all participating countries. Written
informed consent was obtained from all participants.
The design is summarized in Figure 1. For the purpose of
the trial, CAD was defined as previous MI or history of angina
with evidence of multivessel disease, or multivessel revascu-
larization; and PAD was defined as claudication with objective
evidence of arterial disease, previous amputation or revascu-
larization, previous carotid revascularization, or asymptomatic
carotid disease with at least 50% stenosis (Table 1). Inclusion
and exclusion criteria are listed in Table 2.
Run-in. During the 30-day run-in period, potentially eligible
subjects (excluding those who were randomized 4-14 days
after CABG surgery) received rivaroxaban placebo twice daily
and aspirin 100 mg once daily. Study pantoprazole/pan-
toprazole placebo was not administered during the run-in.
Randomization. Subjects who successfully completed the
run-in period (defined as at least 80% adherence to treatment)R
Rivaroxaban 2.5 mg bid 
+ Aspirin 100 mg od
Aspirin 100 mg od
Rivaroxaban 5 mg bid
Screening 
Period
Run-in
period
No 
PPI 
R
Pantoprazole 40 mg od
Placebo od
Screening 
Period
Run-in
period
Continue PPI 
PPI 
A
B
Figure 1. The trial randomized 27,395 subjects with prevalent
vascular disease (coronary or peripheral artery disease) in a 3  2
partial factorial design. (A) All subjects were ran-domized in a 1:1:1
ratio to receive 1 of the 2 rivaroxaban arms vs aspirin stratified ac-
cording to centre and PPI use. The primary efficacy outcome for the
rivaroxaban/aspirin randomization was the composite of myocardial
infarction, stroke, or cardiovascular death, and the main safety
outcome was major bleeding defined according to modified Interna-
tional Society on Thrombosis and Haemostasis (ISTH) criteria. (B)
Subjects were randomized in a 1:1 ratio to receive pantoprazole or
pantoprazole placebo if they had no continuous need for a proton
pump inhibitor (PPI). The main outcome for the pantoprazole
randomization was a composite of upper gastrointestinal tract com-
plications. bid, twice daily; od, once daily; R, randomization.and who consented to continue in the study, as well as those
enrolled after CABG were randomized in a 1:1 ratio to receive
pantoprazole or pantoprazole placebo, if they had no
continuous need for a proton pump inhibitor. All subjects
were randomized in a 1:1:1 ratio to receive 1 of the 2 rivar-
oxaban arms vs aspirin in a 1:1:1 ratio stratified according to
centre and proton pump inhibitor use.
Subjects randomized early after CABG surgery. Partici-
pants randomized soon after CABG surgery underwent the
same screening, follow-up, and washout periods as other
COMPASS trial participants except that they did not undergo
a run-in. The run-in was not required because thrombotic
graft occlusion that can potentially be prevented by rivarox-
aban is believed to occur during the first few weeks after
CABG surgery and a run-in would delay the start of rivar-
oxaban. Most of these subjects underwent screening during
the 2-3 weeks before surgery or in the days immediately after
surgery and before randomization.
COMPASS CABG participants were randomized between
days 4 and 14 after surgery and at least 24 hours after removal
of chest tube and at least 12 hours after the last administration
of any anticoagulant (including venous thromboembolism
prophylaxis). All participants randomized 4-14 days after
CABG surgery were required to undergo coronary computed
tomography angiography to evaluate graft patency at 1 year as
part of the study protocol unless they had already undergone
conventional angiography as part of their usual medical care or
they had a specific contraindication for computed tomography
angiography (eg, contrast allergy, estimated glomerular filtra-
tion rate < 30 mL/min/1.73 m2).
Outcomes. The primary efficacy outcome for the rivaroxaban
randomization is the composite of MI, stroke, or CV death.
The primary safety outcome is based on a modification of the
International Society on Thrombosis and Haemostasis (ISTH)
Table 3. Secondary and tertiary outcomes for the rivaroxaban/aspirin
randomization
Secondary outcomes
 Coronary heart disease death, myocardial infarction, ischemic stroke, acute
limb ischemia
 Cardiovascular death, myocardial infarction, ischemic stroke, acute limb
ischemia
 All-cause mortality
Tertiary
 Subject-reported Standard Assessment of Global Activities in the Elderly,
Montreal Cognitive Assessment, Digital Symbol Substitution, European
Quality of Life-5 Dimensions, Interheart Diet Questionnaire, International
Physical Activity Questionnaire
 Individual components of the primary and secondary outcomes
 Hospitalization for cardiovascular reasons
 All-cause hospitalizations
 Arterial revascularization
 Limb amputation
 Stent thrombosis
 Unstable angina
 Worsening angina
 New angina
 New heart failure
 Venous thromboembolic events
 Resuscitated cardiac arrest
 New diagnosis of cancer
Table 2. Eligibility criteria
Inclusion criteria
 Willing and able to provide written informed consent
 Meet criteria for CAD and/or PAD (see Table 1)
Subjects with CAD must also meet at least 1 of the following criteria:
 Age 65 years or older, or
 Age younger than 65 years and documented atherosclerosis or revascularization involving at least 2 vascular beds* or at least 2 additional risk factors:
(1) Current smoker (within 1 year of randomization)
(2) Diabetes mellitus
(3) Renal dysfunction with estimated glomerular filtration rate < 60 mL/min
(4) Heart failure
(5) Nonlacunar ischemic stroke  1 month ago
Exclusion criteriay
 High risk of bleeding
 Stroke within 1 month or any history of hemorrhagic or lacunar stroke
 Severe heart failure with known ejection fraction < 30% or New York Heart Association class III or IV symptoms
 Estimated glomerular filtration rate < 15 mL/min
 Need for dual antiplatelet therapy, other nonaspirin antiplatelet therapy, or oral anticoagulant therapy
 Known noncardiovascular disease that is associated with poor prognosis (eg, metastatic cancer) or that increases the risk of an adverse reaction to study
interventions
 History of hypersensitivity or known contraindication for rivaroxaban, aspirin, pantoprazole, or excipients, if applicable
 Systemic treatment with strong inhibitors of CYP 3A4 as well as p-glycoprotein (eg, systemic azole antimycotics, such as ketoconazole, and HIV-protease
inhibitors, such as ritonavir), or strong inducers of CYP 3A4 (ie, rifampicin, rifabutin, phenobarbital, phenytoin, and carbamazepine)
 Any known hepatic disease associated with coagulopathy
 Subjects who are pregnant, breastfeeding, or are of childbearing potential, and sexually active and not practicing an effective method of birth control (eg,
surgically sterile, prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner
sterilization)
 Previous assignment to treatment during this study
 Concomitant participation in another study with investigational drug
 Known contraindication to any study-related procedures
CAD, coronary artery disease; CYP, Cytochrome P; PAD, peripheral artery disease.
* Because CAD involves disease in the coronary vasculature, only 1 additional vascular bed is required (eg, the aorta, arterial supply to the brain, gastro-intestinal
tract, lower limbs, upper limbs, kidneys).
yUse of a proton pump inhibitor excluded participation in the pantoprazole randomization.
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bleeding in a critical organ, or bleeding into the surgical site
requiring reoperation, and bleeding leading to hospitalization
(includes presentation to an acute care facility without over-
night stay). Secondary and tertiary outcomes for the rivarox-
aban/aspirin randomization are listed in Table 3.
The main outcome for the pantoprazole randomization
is the composite of overt bleeding of GI origin confirmed using
endoscopy or radiography, overt upper GI bleeding
of unknown origin, bleeding of presumed occult GI origin with
documented decrease of hemoglobin of 2 g/dL from baseline,
symptomatic gastroduodenal ulcer, GI pain with underlying
multiple gastroduodenal erosions, and obstruction or perfora-
tion. Safety outcomes for the pantoprazole and pantoprazole
placebo arms of the study are listed in Table 4.
Definitions of study outcomes are provided in
Supplemental Appendix S1.
Follow-up. Participants were seen at 1 and 6 months after
randomization, and at 6-month intervals thereafter to record
outcomes and adverse events, and enhance adherence. Addi-
tional follow-up visits were conducted via telephone at 3 and 9
months. Validated questionnaires were administered at
randomization and at month 24 to collect data on subject health
and quality of life (Standard Assessment of Global Activities in
the Elderly, Montreal Cognitive Assessment, Digital Symbol
Substitution, European Quality of Life-5 Dimensions, Inter-
heart Diet Questionnaire, and the short form of the Interna-
tional Physical Activity Questionnaire). Functional and
cognitive questionnaires were repeated at the visit after a primaryoutcome event and also at study end. All subjects are followed
for the duration of the study irrespective of whether they
received study treatments or whether an event has occurred.
The final washout period visit is being conducted by
telephone 30 days after the final follow-up visit. The purpose
of the washout visit is to collect information on outcomes and
Table 5. COMPASS participant baseline characteristics
Characteristic Value
Participant n 27,395
Mean age (SD), years 68.2 (7.94)
Male sex 21,375 (78)
Mean heart rate (SD), beats per minute 67.6 (10.65)
Mean SBP (SD), mm Hg 135.5 (17.57)
Mean DBP (SD), mm Hg 77.6 (9.98)
Body mass index 28.3 (4.74)
ABI < 0.9 3643 (13.3)
Mean cholesterol (SD), mmol/L 4.3 (3.51)
Mean creatinine (SD), mmol/L 90.7 (54.12)
Mean eGFR (SD), mL/min/1.73m2 73.8 (17.9)
Current smoking 5866 (21.4)
Hypertension 20,627 (75.3)
Diabetes 10,340 (37.7)
CAD history 24,825 (90.6)
Previous MI 17,022 (62.1)
Mean time since last MI (SD), years 7.1 (6.46)
Previous CABG surgery 6470 (23.5)
Heart failure history 5900 (21.5)
Stroke history 1033 (3.8)
PAD history 7470 (27.3)
Asymptomatic carotid stenosis > 50% 1917 (7)
Peptic ulcer history 1237 (4.5)
Bleeding requiring transfusion 723 (2.6)
Region
North America 3918 (14.3)
South America 6144 (22.4)
Western Europe 8555 (31.2)
Eastern Europe 4823 (17.6)
Asia/Pacific 3955 (14.4)
Data are presented as n (%) except where otherwise stated.
ABI, ankle brachial index; CABG, coronary artery bypass graft; CAD,
coronary artery disease; COMPASS, Cardiovascular Outcomes for People
Using Anticoagulation Strategies; eGFR, estimated glomerular filtration rate;
MI, myocardial infarction; PAD, peripheral artery disease; SBP, systolic blood
pressure.
Table 4. Safety outcomes for the pantoprazole randomization
Safety outcomes
 Gastric atrophy
 Pneumonia
 Clostridium difficile infections
 Other enteric infections
 Bone fractures
New diagnosis since randomization of:
 Chronic kidney disease
 Diabetes
 Chronic obstructive lung disease
 Dementia
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discontinuation of investigational treatment.
Sample size. COMPASS is an event-driven trial that is
designed to continue until at least 2200 participants expe-
rience a confirmed primary efficacy outcome. The originally
planned sample size of 19,500 subjects was on the basis of
the following assumptions for the antithrombotic treatment
randomization: a 3-arm study with 1:1:1 randomization,
2-sided overall type I error level of 5%, an annual event rate
in the aspirin control group of 4.0%-4.5%,3,29 90% power
on the basis of a 20% relative risk reduction for each of the 2
comparisons of rivaroxaban vs aspirin. The expectation for
the duration of recruitment was approximately 2.5 years,
and for permanent discontinuation of study drug was 6% in
the first 6 months, 4% in the second 6 months, and 3%
during each 6-month period thereafter. On the basis of
slower than expected recruitment rate and a lower than ex-
pected aggregate incidence of the primary outcome of 2.9%,
the sample size was increased to 27,400 subjects in July
2015. We projected that we would reach the target number
of primary efficacy outcome events in the first quarter
of 2018.
For the comparison of pantoprazole vs its placebo, we
assumed an annual incidence risk for major upper GI com-
plications of 1.6%-2.2%,10 and with randomization of at least
14,000 subjects to pantoprazole or pantoprazole placebo we
expected that at least 500 events would accrue during follow-
up, resulting in at least 90% power to detect a 50% relative
risk reduction using a 2-sided type I error level of 5%.
Analyses. Analysis of the primary outcome will be based on
the intention to treat principle. Comparisons will be per-
formed between each of the rivaroxaban-based treatment and
the common aspirin control group. These 2 comparisons will
be performed using 2 separate stratified log rank tests. Proton
pump inhibitor use will be used as a stratification factor. To
address the multiplicity related to the testing of 2 primary and
secondary hypotheses, a mixture gatekeeping procedure on the
basis of the Hochberg test will be used to control the fam-
ilywise error rate of a ¼ 5%.30
Kaplan-Meier estimates of cumulative risk and cumulative
hazard function will be provided to evaluate the timing of event
occurrences in the 3 antithrombotic treatment groups and the
consistency of the respective treatment effects at all time points.
HR, relative risk reduction, and corresponding 95% confidence
intervals will be estimated on the basis of 2 separate stratified
Cox proportional hazards models.Details of the statistical approach are provided in the sta-
tistical analysis plan.
Data Safety and Monitoring Board. An independent Data
Safety and Monitoring Board (DSMB) is monitoring the study
for safety and efficacy. Two formal interim analyses are planned
to assess efficacy of the rivaroxaban/aspirin arms when approx-
imately 50% and 75% of primary efficacy outcomes have
accrued. For efficacy, the primary outcome is monitored using a
modified Haybittle-Peto rule using 4 SDs for the first interim
analysis and 3 SDs for the second analysis. If the observed
relative risk for the primary efficacy outcome at 1 of the pre-
specified interim analyses crosses the critical value obtained using
the corresponding modified Haybittle-Peto boundary, another
analysis will be performed 3-6 months later; if the observed
relative risk again crosses the critical value then the DSMB could
recommend that the trial be terminated for efficacy of
rivaroxaban-based therapy. No formal boundaries were set for
terminating the study for safety reasons but clear and consistent
evidence of a net harm that overwhelms any benefit should be
apparent. Because of the extreme nature of the monitoring
boundaries, the need to cross the boundary on 2 occasions and
the paucity of interim analyses, no material adjustment of the
significance level of the final analysis is required.
Baseline characteristics. The trial randomized 27,395 pa-
tients from 602 centres in 33 countries between March 2013
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presented in Table 5. The mean age at enrollment was 68.2
years, 22.0% were female, 90.6% had a history of CAD, and
27.3% had a history of PAD. A total of 1448 subjects were
randomized within 4-14 days after CABG surgery and
17,598 were randomized to pantoprazole or pantoprazole
placebo.
Substudy: COMPASS MIND
The effect of the intervention on incident covert infarcts in
the brain (ie, infarcts unrecognized clinically but identified on
cerebral imaging)31 will be examined in a subgroup of
COMPASS participants with baseline magnetic resonance
imaging. Details of the design of this substudy will be pub-
lished separately.
Study management
The trial is independently managed by the PHRI and a
Steering Committee in collaboration with the sponsor, Bayer
AG. The trial is registered at www.clinicaltrials.gov
(NCT01776424). Members of the Operations Committee,
Steering Committee, DSMB, and the staff at the PHRI
Project Office and Bayer AG involved in the conduct of the
study are listed in Supplemental Appendix S2.Discussion
The COMPASS trial tests if rivaroxaban-based therapy
compared with aspirin prevents CV events and also tests if a
proton pump inhibitor compared with placebo reduces upper
GI complications in patients with stable CAD or PAD. Pre-
vious attempts to improve the efficacy of antithrombotic
therapy for long-term secondary CV prevention using com-
binations of antiplatelet drugs and combinations of an anti-
platelet drug and warfarin have had limited success; they did
not improve efficacy or were associated with modest im-
provements in efficacy, excess bleeding, and no overall mor-
tality benefit. In COMPASS, we hypothesize that the
improvement in efficacy achieved with the combination of
rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily
or rivaroxaban 5 mg twice daily or compared with aspirin
100 mg once daily will outweigh any increase in bleeding.
The safety of antithrombotic therapy for long-term sec-
ondary prevention of CV events might be further improved by
use of a proton pump inhibitor, as is being tested in the
COMPASS partial factorial design.
Other unique aspects of the COMPASS trial include
assessment of the effect of rivaroxaban on graft patency in
COMPASS CABG and on covert brain ischemia in COM-
PASS MIND. CABG surgery remains the definitive treatment
for patients with advanced CAD, but is limited by early graft
failure. Aspirin has been proven to prevent early graft failure,
but graft failure rates remain high despite its use. The
COMPASS CABG substudy will test whether antithrombotic
therapy with or without concomitant aspirin will improve
1-year graft patency compared with aspirin alone. The
COMPASS MIND magnetic resonance imaging substudy is
highly relevant because of the growing burden of unrecog-
nized brain ischemia and related complications in the aging
world population. Covert stroke is a major cause of cognitiveloss, and the prevention of covert stroke using rivaroxaban
might also help to prevent cognitive decline.
In conclusion, the COMPASS trial program is testing
whether a vascular protective dose of rivaroxaban, with or
without antiplatelet therapy with aspirin, can reduce major
cardiac adverse events in patients with stable CAD and PAD.
At the same time, it tests strategies to improve the safety of
antithrombotic therapies by preventing GI bleeding. The re-
sults are likely to provide definitive information that will affect
multiple guidelines32-34 and will change clinical practice.Acknowledgements
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